NovoCure Limited (NVCR)

Market Cap	1.82B
Revenue (ttm)	577.74M
Net Income (ttm)	-149.78M
Shares Out	108.20M
EPS (ttm)	-1.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	645,678
Open	16.26
Previous Close	16.48
Day's Range	16.22 - 17.35
52-Week Range	11.29 - 24.74
Beta	0.70
Analysts	Buy
Price Target	26.60 (+57.77%)
Earnings Date	Oct 30, 2024

About NVCR

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporate...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 2, 2015
• Employees: 1,453
• Stock Exchange: NASDAQ
• Ticker Symbol: NVCR
• Website: https://www.novocure.com

Financial Performance

In 2023, NovoCure's revenue was $509.34 million, a decrease of -5.30% compared to the previous year's $537.84 million. Losses were -$207.04 million, 123.7% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for NVCR stock is "Buy." The 12-month stock price forecast is $26.6, which is an increase of 57.77% from the latest price.

Price Target

$26.6

(57.77% upside)

Analyst Consensus: Buy